Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment

Liu, Sheng-Xuan; Li, Yin-Hu; Dai, Wen-Kui; Li, Xue-Song; Qiu, Chuang-Zhao; Ruan, Meng-Ling; Zou, Biao; Dong, Chen; Liu, Yan-Hong; He, Jia-Yi; Huang, Zhi-Hua; Shu, Sai-Nan

Published in:
World Journal of Gastroenterology

Published: 28/12/2017

Document Version:
Final Published version, also known as Publisher’s PDF, Publisher’s Final version or Version of Record

License:
CC BY-NC

Publication record in CityU Scholars:
Go to record

Published version (DOI):

Publication details:

Citing this paper
Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights
Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.

Publisher permission
Permission for previously published items are in accordance with publisher's copyright policies sourced from the SHERPA RoMEO database. Links to full text versions (either Published or Post-print) are only available if corresponding publishers allow open access.

Take down policy
Contact lbscholars@cityu.edu.hk if you believe that this document breaches copyright and provide us with details. We will remove access to the work immediately and investigate your claim.
EDITORIAL
8439  Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis
Miranda AS, Simões e Silva AC

MINIREVIEWS
8443  Mechanisms of autophagy activation in endothelial cell and their targeting during normothermic machine liver perfusion

ORIGINAL ARTICLE
Basic Study
8452  Human small intestine is capable of restoring barrier function after short ischemic periods
Schellekens DH, Hundscheid IH, Leenarts CA, Grootjans J, Lenaerts K, Buurman WA, Dejong CH, Deriks JP

8465  Stable gastric pentadecapeptide BPC 157 in treatment of colitis and ischemia and reperfusion in rats: New insights

8489  Exploring pathogenesis of primary biliary cholangitis by proteomics: A pilot study

8500  Influence of TBX21 T-1993C variant on autoimmune hepatitis development by Yin-Yang 1 binding
Sun W, Wu HY, Chen S

8512  Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts

Retrospective Cohort Study
8526  Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients

Retrospective Study
8533  Analysis of 12 variants in the development of gastric and colorectal cancers
Cavalcante GC, Amador MA, Ribeiro dos Santos AM, Carvalho DC, Andrade RB, Pereira EE, Fernandes MR, Costa DF, Santos NP, Assumpção PP, Ribeiro dos Santos Â, Santos S
### Contents

**World Journal of Gastroenterology**  
**Volume 23  Number 48  December 28, 2017**

- **8544** Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene  
  *Ohya T, Yanagimachi M, Iwasawa K, Umetsu S, Sogo T, Inui A, Fujisawa T, Ito S*

- **8553** Comparison of totally laparoscopic total gastrectomy using an endoscopic linear stapler with laparoscopic-assisted total gastrectomy using a circular stapler in patients with gastric cancer: A single-center experience  
  *Gong CS, Kim BS, Kim HS*

- **8562** Prognostic significance of pretreatment serum carcinoembryonic antigen levels in gastric cancer with pathological lymph node-negative: A large sample single-center retrospective study  
  *Xiao J, Ye ZS, Wei SH, Zeng Y, Lin ZM, Wang Y, Teng WH, Chen LC*

- **8570** Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment  
  *Liu SX, Li YH, Dai WK, Li XS, Qiu CZ, Ruan ML, Zou B, Dong C, Liu YH, He JY, Huang ZH, Shu SN*

- **8582** Prognostic value of lymph node metastasis in patients with T1-stage colorectal cancer from multiple centers in China  
  *Sun ZQ, Ma S, Zhou QB, Yang SX, Chang Y, Zeng XY, Ren WG, Han FH, Xie X, Zeng FY, Sun XT, Wang GX, Li Z, Zhang ZY, Song JM, Liu JB, Yuan WT*

**Clinical Trial Study**

- **8591** Association between acute pancreatitis and small intestinal bacterial overgrowth assessed by hydrogen breath test  
  *Zhang M, Zhu HM, He F, Li BY, Li XC*

**Observational Study**

- **8597** Endoscopic papillary large balloon dilatation with sphincterotomy is safe and effective for biliary stone removal independent of timing and size of sphincterotomy  
  *Aujla UI, Ladep N, Dwyer L, Hood S, Stern N, Sturgess R*

- **8605** Person-centered endoscopy safety checklist: Development, implementation, and evaluation  
  *Dubois H, Schmidt PT, Creutzfeldt J, Bergenmar M*

**Randomized Clinicalled Trials**

- **8615** Multicenter, randomized study to optimize bowel preparation for colon capsule endoscopy  
  *Kastenberg D, Burch WC, Romeo DP, Kashyap PK, Pound DC, Papageorgiou N, Fernández-Urrien Sainz I, Sokach CE, Rex DK*
SYSTEMATIC REVIEWS

8626  Fusobacterium’s link to colorectal neoplasia sequenced: A systematic review and future insights
Hussan H, Clinton SK, Roberts K, Bailey MT

8651  Psychiatric morbidity after surgery for inflammatory bowel disease: A systematic review
Zangenberg MS, El-Hussuna A

CASE REPORT

8660  Strictureing Crohn's disease-like colitis in a patient treated with belatacept
Le Quintrec M, Blanc P, Pineton de Chambrun G

8666  Emphysematous pancreatitis associated with penetrating duodenal ulcer
Tana C, Silingardi M, Giamberardino MA, Cipollone F, Meschi T, Schiavone C

8671  Infiltrative xanthogranulomatous cholecystitis mimicking aggressive gallbladder carcinoma: A diagnostic and therapeutic dilemma
Retrospective Study

Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment

Sheng-Xuan Liu, Yin-Hu Li, Wen-Kui Dai, Xue-Song Li, Chuang-Zhao Qiu, Meng-Ling Ruan, Biao Zou, Chen Dong, Yan-Hong Liu, Jia-Yi He, Zhi-Hua Huang, Sai-Nan Shu

Sheng-Xuan Liu, Xue-Song Li, Meng-Ling Ruan, Biao Zou, Chen Dong, Jia-Yi He, Zhi-Hua Huang, Sai-Nan Shu, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

Yin-Hu Li, Chuang-Zhao Qiu, Yan-Hong Liu, Department of Microbial Research, WeHealthGene Institute, Shenzhen 518000, Guangdong Province, China

Wen-Kui Dai, Department of Computer Science, College of Science and Engineering, City University of Hong Kong, Hong Kong, China

ORCID number: Sheng-Xuan Liu (0000-0001-7084-2711); Yin-Hu Li (0000-0001-6378-6571); Wen-Kui Dai (0000-0002-9723-1416); Xue-Song Li (0000-0003-1567-0763); Chuang-Zhao Qiu (0000-0001-5560-0992); Meng-Ling Ruan (0000-0001-5386-8012); Biao Zou (0000-0002-0770-0988); Chen Dong (0000-0003-0363-7712); Yan-Hong Liu (0000-0001-7705-155X); Jia-Yi He (0000-0003-0712-7277); Zhi-Hua Huang (0000-0002-2016-039X); Sai-Nan Shu (0000-0001-9940-5443).

Author contributions: Liu SX and Li YH contributed equally to this work; Shu SN and Huang ZH designed the research; Dai WK designed the follow-up plans and collected patients’ information with Li XS, Ruan ML, Zou B and Dong C after FMT; Qiu CZ, Liu YH and He JY performed bioinformatics analysis; Ruan ML and Zou B recorded patients’ and donors’ clinical data; Shu SN and Huang ZH conducted FMT.

Supported by National Clinical Key Specialty Construction Project (Pediatric Digestive Disease), No. [2011]873.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (IRB ID: TJ-C20140712).

Informed consent statement: All studied participants, or their legal guardians, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All authors declare that they have no competing interests.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Sai-Nan Shu, MD, PhD, Associate Professor, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Wuhan 430030, Hubei Province, China. snshu@tjh.tjmu.edu.cn

Telephone: +86-27-83662688
Fax: +86-27-83662640

Received: September 5, 2017
Peer-review started: September 5, 2017
First decision: September 27, 2017
Revised: November 2, 2017
Accepted: November 8, 2017
Article in press: November 8, 2017
Published online: December 28, 2017

Abstract

AIM

To investigate the impact of fecal microbiota trans-
plantation (FMT) treatment on allergic colitis (AC) and gut microbiota (GM).

METHODS
We selected a total of 19 AC infants, who suffered from severe diarrhea/hematochezia, did not relieve completely after routine therapy or cannot adhere to the therapy, and were free from organ congenital malformations and other contraindications for FMT. Qualified donor-derived stools were collected and injected to the AC infants via a rectal tube. Clinical outcomes and follow-up observations were noted. Stools were collected from ten AC infants before and after FMT, and GM composition was assessed for infants and donors using 16S rDNA sequencing analysis.

RESULTS
After FMT treatment, AC symptoms in 17 infants were relieved within 2 d, and no relapse was observed in the next 15 mo. Clinical improvement was also detected in the other two AC infants who were lost to follow-up. During follow-up, one AC infant suffered from mild eczema and recovered shortly after hormone therapy. Based on the 16S rDNA analysis in ten AC infants, most of them (n = 6) had greater GM diversity after FMT. As a result, Proteobacteria decreased (n = 6) and Firmicutes increased (n = 10) in post-FMT AC infants. Moreover, Firmicutes accounted for the greatest proportion of GM in the patients. At the genus level, Bacteroides (n = 6), Escherichia (n = 8), and Lactobacillus (n = 4) were enriched in some AC infants after FMT treatment, but the relative abundances of Clostridium (n = 5), Veillonella (n = 7), Streptococcus (n = 6), and Klebsiella (n = 8) decreased dramatically.

CONCLUSION
FMT is a safe and effective method for treating pediatric patients with AC and restoring GM balance.

Key words: Pediatric; Infantile allergic colitis; Fecal microbiota transplantation; Gut microbiota; Immune reaction

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This retrospective study explored the therapeutic effects and safety of fecal microbiota transplantation (FMT) treatment in 19 allergic colitis (AC) infants who were younger than 1 year old. After FMT treatment, AC symptoms were relieved in the patients rapidly, and no patient relapsed within 15 mo. With gut microbiota (GM) analysis, six of ten patients exhibited higher microbial diversity after FMT treatment. Moreover, decreased Proteobacteria and increased Firmicutes supplied the hints of GM re-establishment in the patients after FMT treatment. Therefore, this work showed the curative effects of FMT in AC infants and its possible mechanism.

INTRODUCTION
Allergic colitis (AC) is a common infantile rectal bleeding disorder which is caused by severe allergic reactions within the digestive system[1,2]. AC is normally identified in infants younger than one year of age and its representative clinical features are hematochezia and diarrhea[3]. Bloody purulent stools, abdominal pain, and vomiting are also used to diagnose AC[3]. Various factors such as food allergens, aberrant immune system, and imbalanced gut microbiota (GM) are thought to contribute to AC[4-6].

Conventional therapies for AC are reducing exposure to suspicious allergens and applying hypoallergenic milk powder[7]. Baldassarre et al[8] used probiotics to treat AC infants and found that Lactobacillus GG may relieve symptoms of AC by altering GM composition[8]. Fecal microbiota transplantation (FMT) can change gut micro-ecology more robustly in comparison to food or probiotics. Several reports suggested that FMT was therapeutically efficacious for treating diseases associated with GM dysbiosis, such as Clostridium difficile infection (CDI)[9,10], inflammatory bowel disease (IBD)[11,12], and irritable bowel syndrome (IBS)[13,14]. However, to our knowledge, FMT has not been used to treat AC infants.

Thus, we assessed 19 AC infants with severe hematochezia and/or diarrhea, who had not acquired complete remission after 2 wk of routine therapy or because the guardians cannot adhere to the routine therapy thoroughly. Our intention was to confirm the safety and efficacy of FMT in AC treatment, and detect the sustained GM changes after FMT.

MATERIALS AND METHODS

Ethics
This study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-C20140712). All subjects and donors gave signed informed consent. Principles of patients care and all experimental procedures followed the guidelines established by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Patient selection
AC was diagnosed based on the following clinical symptoms: (1) rectal bleeding with/without mucus and diarrhea; (2) exclusion of infectious colitis, anal fissure, lymphoid nodular hyperplasia, and uncommon conditions such as necrotizing enterocolitis, Hirschsprung's enterocolitis, IBD\(^{[15]}\), and IBS\(^{[16]}\); (3) clinical remission after milk exclusion and recurrence after milk re-challenge\(^{[3,17]}\); and (4) histological examination indicated that the intestinal mucosa exhibited chronic inflammation with eosinophils infiltration and colonic lesions (Supplementary File 1). Pediatric AC patients meeting the following criteria were selected as FMT candidates: (1) the patients had no complete remission after routine therapy, the patients cannot adhere to the therapy thoroughly, or their parents had strong intention to receive the treatment of FMT; (2) free from contraindications for FMT, such as intestinal obstructions, perforations, and bleeding, or severe immunodeficiency diseases; and (3) colonoscopic inspection indicated no mucosal congestion, edema, multiple spot-like erosion, or lymphoid granular nodes (four cases included in Figure 1). As a result, 19 AC patients were enrolled in the study between September 2015 and December 2015 (Table 1).

Donor screening
Patients' mothers were considered to be donors of the highest priority, followed by fathers and healthy peers. Adult donors were screened as follows\(^{[18-20]}\): (1) no infectious diseases history (e.g., tuberculosis and hepatopathy); (2) no metabolic diseases history (e.g., obesity and diabetes); (3) no gastrointestinal diseases (e.g., diarrhea, constipation, IBD, IBS, colorectal polyps, and gastrointestinal tumors); (4) no allergic diseases (e.g., food allergy, eczema, and allergic gastroenteritis); (5) no antibiotic exposure in the last 3 months; (6) no mental disorders or autoimmune diseases; and (7) no drug abuse history, amenorrhea (for mother donors), or psychological imbalance.

Candidate donors of the same age were selected with the following criteria\(^{[18-20]}\): (1) preferred relatives with breast milk fed and same gender; (2) no antibiotic treatment in the last 3 months; (3) no allergic disease (e.g., food allergy, eczema, and allergic gastroenteritis); (4) no gastrointestinal disease (e.g., diarrhea, constipation, IBD, IBS, colorectal polyps, and gastrointestinal tumors); (5) no metabolic disease history (e.g., obesity and diabetes); and (6) no infectious disease history (e.g., tuberculosis, hepatopathy, and measles), and normal health and development. Tests for serum biochemistry and stool were performed for donors to ensure subject safety (Table 2).

FMT procedure
The application of parenteral nutrition and probiotics was stopped as soon as FMT began in the patients. No bowel preparation (cleanout or antibiotic pretreatment) was used prior to FMT, but pre-FMT clinical tests were performed as described in Table 3. Donor stool, collected 2 h before FMT, was diluted and mixed with sterile saline (1 mg of stool was diluted with 3 mL of saline). Samples were filtered through sterile gauze and 30-50 mL fecal suspension was prepared for FMT. FMT was administered over 5-10 min via a rectal tube into the left colon. The rectal tube was removed 15 min after administration and the fecal suspension was retained in the recipients' gut for 4-6 h. Multi-FMT was given for patients with severe symptoms (Table 1).

Follow-up
Clinical symptoms, stool frequency, symptom remission time, and adverse events (e.g., abdominal pain, gastrointestinal infection, constipation, fever, and allergic disease) were recorded at the end of FMT (Table 1). Follow-up was conducted at ≥15 mo after FMT, except for two cases with 0.3 and 0.5 mo follow-up (AC17 and AC19), to evaluate FMT efficacy and safety (Table 1). The remission of AC was defined as the cease of rectal bleeding and decreased stool frequency (no more than two times/d) in the patients. The primary endpoint was the improved AC symptoms and sustained clinical remission at 12 mo. Secondary endpoint was the safety of FMT which was implied by the occurrence of adverse events.

Microbiota analysis and statistics
Fecal microbiota was analyzed for ten patients before FMT and during follow-ups. Donor feces were also assayed for GM. Microbial DNA was extracted using a PowerSoil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) according to the manufacturer's protocol and the hyper-variable V3-V4 region was amplified using 338F (5'-ACTCCTACGGGAGGCAGCA-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3') primers. Library construction and sequencing were conducted on an Illumina MiSeq platform (Illumina, San Diego, United States). Data filtration and sequencing were performed as a prior report with the RDP database as an annotation reference\(^{[21]}\). A Wilcoxon signed-rank test was used to compare samples of one patient, which were collected at different time points, and a Wilcoxon rank-sum test was used to compare donor and patient samples. Graphs were produced with R.
patients, and decreased defecation frequency with improved stool consistency was also observed (Table 1). Within more than 15 mo of follow-up, the symptoms of AC had not relapsed except two patients who were lost to follow-up (AC17 and AC19). Only one patient suffered from eczema, which appeared 2 mo after FMT and was resolved with hormone therapy. Beyond this, no other adverse event was recorded during FMT or the follow-up.

FMT treatment associated microbiota changes
Figures 2 and 3 depict microbiota changes of ten patients before and after FMT compared to donors. Microbiota diversity increased dramatically in five patients while it decreased in three patients after FMT (Figure 2). When sampled 1 or 2 mon after FMT, microbiota of six patients was more similar to donors’ microflora by comparison with pre-FMT samples (Figure 3).

After FMT treatment, Firmicutes accounted for the greatest proportion of GM in the AC infants, followed

package (version 3.2.3).

RESULTS

Recipient characteristics
FMT recipients were aged from 4 to 11 mo (11 boys and 8 girls) and had hematochezia or severe diarrhea. Disease duration of AC patients was 0.5-3 mo for 16 cases and 3-6 mo for three cases (Table 1). Formula was replaced with hypoallergenic milk powder in all patients’ dietary, and 11 of them were exposed to probiotics before FMT treatment (Table 1). The colonoscopic inspection of four AC infants was included in Figure 1.

FMT safety and efficacy
Infants experienced low-quality sleep and weight loss since the onset of AC, but no one was malnourished. They had significant clinical remission within 2 d after the first FMT treatment (Table 1). After FMT, hematochezia or diarrhea rapidly improved in AC patients, and decreased defecation frequency with improved stool consistency was also observed (Table 1). Within more than 15 mo of follow-up, the symptoms of AC had not relapsed except two patients who were lost to follow-up (AC17 and AC19). Only one patient suffered from eczema, which appeared 2 mo after FMT and was resolved with hormone therapy. Beyond this, no other adverse event was recorded during FMT or the follow-up.

FMT treatment associated microbiota changes
Figures 2 and 3 depict microbiota changes of ten patients before and after FMT compared to donors. Microbiota diversity increased dramatically in five patients while it decreased in three patients after FMT (Figure 2). When sampled 1 or 2 mon after FMT, microbiota of six patients was more similar to donors’ microflora by comparison with pre-FMT samples (Figure 3).

After FMT treatment, Firmicutes accounted for the greatest proportion of GM in the AC infants, followed
<table>
<thead>
<tr>
<th>ID</th>
<th>Gender</th>
<th>Age (mo)</th>
<th>Symptom(s)</th>
<th>Duration of disease (mo)</th>
<th>Treatment(s) before FMT</th>
<th>Donor source</th>
<th>FMT times</th>
<th>Symptom remission after first FMT (d)</th>
<th>Stool frequency before and after FMT (times/d)</th>
<th>Follow-up (mo)</th>
<th>Availability of gut microbiota data</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC1</td>
<td>Female</td>
<td>7</td>
<td>Diarrhea, hematochezia</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Mother</td>
<td>2</td>
<td>1</td>
<td>3-4, 1</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>AC2</td>
<td>Male</td>
<td>10</td>
<td>Hematochezia</td>
<td>&gt; 0.5</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria)</td>
<td>Healthy infants aged 10 mo old</td>
<td>2</td>
<td>1</td>
<td>2-3, 1</td>
<td>18</td>
<td>Yes</td>
</tr>
<tr>
<td>AC3</td>
<td>Female</td>
<td>11</td>
<td>Hematochezia</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Healthy infants aged 8 mo old</td>
<td>3</td>
<td>1</td>
<td>5-6, 2</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>AC4</td>
<td>Male</td>
<td>9</td>
<td>Hematochezia</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Mother's cousin sister</td>
<td>3</td>
<td>1</td>
<td>6-7, 1-2</td>
<td>18</td>
<td>Yes</td>
</tr>
<tr>
<td>AC5</td>
<td>Male</td>
<td>5</td>
<td>Diarrhea and hematochezia sometimes</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Healthy infants aged 8 mo old</td>
<td>3</td>
<td>1</td>
<td>3-4, 2</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>AC6</td>
<td>Male</td>
<td>5</td>
<td>Hematochezia</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Mother</td>
<td>1</td>
<td>2</td>
<td>5-6, 1</td>
<td>18</td>
<td>Yes</td>
</tr>
<tr>
<td>AC7</td>
<td>Male</td>
<td>4</td>
<td>Hematochezia and cough sometimes</td>
<td>&gt; 2</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Mother</td>
<td>2</td>
<td>2</td>
<td>5-6, 1</td>
<td>15</td>
<td>Yes</td>
</tr>
<tr>
<td>AC8</td>
<td>Female</td>
<td>3</td>
<td>Diarrhea and mucoid feces sometimes</td>
<td>&gt; 2</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Mother</td>
<td>2</td>
<td>1</td>
<td>3-4, 1-2</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>AC9</td>
<td>Male</td>
<td>11</td>
<td>Interval hematochezia</td>
<td>&gt; 6</td>
<td>Applying amino acid formula and probiotics (S. boulardii)</td>
<td>Mother</td>
<td>2</td>
<td>1</td>
<td>3-4, 2</td>
<td>23</td>
<td>Yes</td>
</tr>
<tr>
<td>AC10</td>
<td>Female</td>
<td>3</td>
<td>Hematochezia</td>
<td>&gt; 1.5</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Healthy infants aged 10 mo old</td>
<td>4</td>
<td>2</td>
<td>5-6, 1</td>
<td>21</td>
<td>Yes</td>
</tr>
<tr>
<td>AC11</td>
<td>Male</td>
<td>7</td>
<td>Diarrhea</td>
<td>&gt; 2</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria, Smectis and Oral Rehydration Salts (ORS))</td>
<td>Healthy infants aged 10 mo old</td>
<td>5</td>
<td>1</td>
<td>5-6, 1</td>
<td>23</td>
<td>No</td>
</tr>
<tr>
<td>AC12</td>
<td>Female</td>
<td>10</td>
<td>Diarrhea and hematochezia sometimes</td>
<td>&gt; 1</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria)</td>
<td>Mother</td>
<td>3</td>
<td>1</td>
<td>5-6, 1-2</td>
<td>22</td>
<td>No</td>
</tr>
<tr>
<td>AC13</td>
<td>Male</td>
<td>5</td>
<td>Hematochezia and diarrhea sometimes</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria)</td>
<td>Mother</td>
<td>1</td>
<td>1</td>
<td>3-4, 1</td>
<td>15</td>
<td>No</td>
</tr>
<tr>
<td>AC14</td>
<td>Female</td>
<td>5</td>
<td>Hematochezia and then peptone shaped feces</td>
<td>&gt; 1</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria)</td>
<td>Mother</td>
<td>1</td>
<td>1</td>
<td>7-8, 2</td>
<td>15</td>
<td>No</td>
</tr>
<tr>
<td>AC15</td>
<td>Male</td>
<td>7</td>
<td>Diarrhea</td>
<td>&gt; 2</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Mother</td>
<td>5</td>
<td>1</td>
<td>5-6, 1</td>
<td>21</td>
<td>No</td>
</tr>
<tr>
<td>AC16</td>
<td>Female</td>
<td>5</td>
<td>Interval hematochezia</td>
<td>&gt; 2</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Healthy infants aged 8 mo old</td>
<td>2</td>
<td>1</td>
<td>4-5, 1</td>
<td>21</td>
<td>No</td>
</tr>
<tr>
<td>AC17</td>
<td>Male</td>
<td>7</td>
<td>Diarrhea and hematochezia sometimes</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria and C. butyricum)</td>
<td>Healthy infants aged 11 mo old</td>
<td>1</td>
<td>2</td>
<td>3-4, 1-2</td>
<td>0.5</td>
<td>No</td>
</tr>
<tr>
<td>AC18</td>
<td>Female</td>
<td>8</td>
<td>Diarrhea and cough sometimes</td>
<td>&gt; 3</td>
<td>Applying amino acid formula and probiotics (Bifidobacteria and C. butyricum)</td>
<td>Healthy infants aged 8 mo old</td>
<td>2</td>
<td>1</td>
<td>3-4, 2</td>
<td>17</td>
<td>No</td>
</tr>
<tr>
<td>AC19</td>
<td>Male</td>
<td>5</td>
<td>Interval diarrhea</td>
<td>&gt; 4</td>
<td>Applying amino acid formula and probiotics (C. butyricum)</td>
<td>Mother</td>
<td>4</td>
<td>1</td>
<td>3-4, 1</td>
<td>0.3</td>
<td>No</td>
</tr>
</tbody>
</table>

AC: Allergic colitis; FMT: Fecal microbiota transplantation.

Liu SX et al. FMT for infantile AC treatment.
Liu SX et al. FMT for infantile AC treatment
by Bacteroidetes and Proteobacteria. Proteobacteria decreased dramatically to < 10% for most patients except four patients (Supplementary File 2). Whilst, Firmicutes increased in all patients (Supplementary File 2).

The relative abundance of *Escherichia* significantly increased in eight AC infants (Supplementary File 3). *Bacteroides* increased in five AC infants including three who had no *Bacteroides* pre-FMT (Supplementary File 3). For four patients, *Lactobacillus* was enriched after FMT, but for three subjects, it was absent even after FMT. Possible pathogens including *Clostridium* and *Klebsiella* generally decreased after FMT. *Clostridium* and *Klebsiella* decreased in five and eight AC infants respectively (Supplementary File 3). The relative abundance of *Streptococcus* was lowered in six patients. Whilst, *Veillonella* was found decreased in seven patients and its relative abundance was no more than

### Figure 2  Shannon rarefaction curves of gut microbiota from ten allergic colitis infants and their donors

Each image represents one AC infant, and each curve represents one fecal sample from a patient or the corresponding donor. Sample ID has three parts: ‘R’ or ‘D’ indicates AC infants or donors, ‘pre’ or ‘post’ represents the stools collected before or after FMT, and fecal collection date. Microbiota diversity in six patients (AC1, AC4, AC5, AC7, AC8, and AC9) increased after FMT treatment.

### Table 2  Laboratory testing on donors

<table>
<thead>
<tr>
<th>Blood testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion examinations: Quantifications of hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B E antigen, hepatitis B E antibody, hepatitis B core IgM antibody, hepatitis C antibody, human immunodeficiency virus antibody, and <em>Treponema pallidum</em> antibody.</td>
</tr>
<tr>
<td>TORCH examinations: Detections on toxoplasmosis IgG, toxoplasmosis IgM, rubella virus IgG, rubella virus IgM, cytomegalovirus IgG, cytomegalovirus IgM, herpes simplex virus 1/2 IgG, and herpes simplex virus 1/2 IgM.</td>
</tr>
<tr>
<td>Detection on parvovirus B19.</td>
</tr>
<tr>
<td>Epstein-Barr virus examinations: Detections on Epstein-Barr virus capsid antigen IgA, Epstein-Barr virus capsid antigen IgG, Epstein-Barr virus capsid antigen IgM, Epstein-Barr virus early antigen IgG, and Epstein-Barr virus nuclear antigen IgG.</td>
</tr>
<tr>
<td>Blood type examination.</td>
</tr>
<tr>
<td>Lymphocyte subpopulation examination.</td>
</tr>
<tr>
<td>Food allergen examination (sIgE).</td>
</tr>
<tr>
<td>Hepatic and renal function examinations: Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, total protein, albumin, globulin, prealbumin, total bilirubin, direct bilirubin, indirect bilirubin, alkaline phosphatase, gamma glutamyltranspeptidase, total cholesterol, triglycerides, high-density lipoprotein, low density lipoprotein, apolipoprotein A1, apolipoprotein B, lactic dehydrogenase, calcium, corrected calcium, phosphorus, magnesium, urea, creatinine, triiodothyronine, bicarbonate radical, total bile acid, 5-nucleotidase, α-L-fucosidase, cholinesterase, cystatin C, and lipase and amylopsin.</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis antibody examination (or the enzyme-linked immuno-spot assay test for tuberculosis).</td>
</tr>
<tr>
<td>Detection on hepatitis A-IgM.</td>
</tr>
<tr>
<td>Qualifications of C-reaction protein and erythrocyte sedimentation rate.</td>
</tr>
</tbody>
</table>

### Stool testing

| Fecal routine examinations: Detections on fecal color, character, red blood cells, white blood cells, occult blood, parasite eggs, protozoa, fat ball, rotavirus antigen, and fungus. |
| Bacterial culture tests: Detections on *Vibrio cholera*, *Salmonella*, *Shigella*, *Aeromonas*, *Plesiomonas*, and pathogenic *Escherichia coli*. |
| Other testing |
| Chest X-ray. |
| *Urea[C13]* Capsule Breath Test. |
| Abdominal ultrasound scan. |
| Electrocardiographic examination. |
Liu SX et al. FMT for infantile AC treatment
DISCUSSION

We chiefly considered the curative effects of FMT therapy in 19 AC infants and microbiota changes during treatment. Stools from both infant and adult donors suggested the same efficacy, and it was noted that all subjects had relieved symptoms of hematochezia and/or diarrhea in 2 d after the first FMT treatment. Due to the longer illness time or sever clinical symptoms, 15 patients experienced multi-FMT for the sustained clinical remission. And the multiple FMT in these patients gave us the idea that artificially modified microbiota for the specified patient might elevate the efficiency of FMT and attenuate transplantation times in the future. After being discharged from hospital, the patients were advised to take hypoallergenic milk powder instead of formula, and most patients had no relapse of colitis within more than 15 mo of follow-up. The recurrence of eczema

8% after FMT. *Bifidobacterium* kept decreased in seven AC infants after FMT, and increased in two cases.

**Figure 3** Microbiota similarity between allergic colitis infants and their donors. Values in red indicate low microbiota similarity between two samples. Blue represents high microbiota similarity. The microbiota compositions of patients (AC1, AC2, AC4, AC5, AC9, AC7, AC8, and AC10) were more similar to their donors’ composition after FMT treatment. One patient (AC9) had more and then less microbiota similarity and AC3 did not change in this regard. AC: Allergic colitis.

**Table 3** Laboratory testing of the patients before fecal microbiota transplantation

<table>
<thead>
<tr>
<th>Blood testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic and renal function examinations: Glutamic-pyruvic transaminas, glutamic oxalacetic transaminase, total protein, albumin, globulin, prealbumin, total bilirubin, direct bilirubin, indirect bilirubin, alkaline phosphatase, gamma glutamyltranspeptidase, total cholesterol, triglycerides, high-density lipoprotein, low density lipoprotein, apolipoprotein A1, apolipoprotein B, lactic dehydrogenase, calcium, corrected calcium, phosphorus, magnesium, urea, creatinine, triosxypurine, bicarbonate radical, total bile acid, 5-nucleotidase, α-1-ducosidase, cholinesterase, cystatin C, lipase, and amylopopsin.</td>
</tr>
<tr>
<td>Food allergen examination (sIgE).</td>
</tr>
<tr>
<td>Lymphocyte subpopulation examination.</td>
</tr>
<tr>
<td>Detection on hepatitis A-IgM.</td>
</tr>
<tr>
<td>TORCH examinations: Detections on toxoplasmosis IgG, toxoplasmosis IgM, rubella virus IgG, rubella virus IgM, cytomegalovirus IgG, cytomegalovirus IgM, herpes simplex virus 1/2 IgG, and herpes simplex virus 1/2 IgM.</td>
</tr>
<tr>
<td>Detection on parvovirus B19.</td>
</tr>
<tr>
<td>Blood coagulation examinations: Detections on prothrombin time, prothrombin activity, international normalized ratio, fibrinogen, activated partial thromboplastin time, thrombin time, and D-dimer.</td>
</tr>
<tr>
<td>Blood type examination.</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis antibody examination (or the enzyme-linked immuno-spot assay test for tuberculosis).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stool testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fecal routine examinations: Detections on fecal color, character, red blood cells, white blood cells, occult blood, parasite eggs, protozoan, fat ball, rotavirus antigen, and fungus.</td>
</tr>
<tr>
<td>Bacterial culture tests: Detections on Vibrio cholera, Salmonella, Shigella, Aeromonas, Plesismonas, and pathogenic Escherichia coli.</td>
</tr>
<tr>
<td>Other testing</td>
</tr>
<tr>
<td>Enteroscopic examination.</td>
</tr>
<tr>
<td>Abdominal ultrasound scan (intestinal adhesion).</td>
</tr>
<tr>
<td>Electrocardiographic examination.</td>
</tr>
</tbody>
</table>
in one infant might be caused by the inflammatory reactions which were triggered by discontinuous intake of hypoallergenic milk powder.

Fecal microbiota was analyzed in ten patients and their donors. We noted that the microbiota diversity increased in six patients after FMT. For three other subjects, GM diversity decreased after an initial increase while all the patients demonstrated clinical improvement. Individual-specific GM changes suggested the effect of donor’s GM complexity and patient’s gut micro-ecology imbalance. Khoruts et al.\(^{[10]}\) also suggested that bacteria can be eliminated due to nutrient competition, antimicrobial peptide suppression, and immune-mediated colonization resistance during GM re-establishment.

Proteobacteria, which contain opportunistic pathogens\(^{[22]}\), decreased in six AC infants, and their relative abundance was less than 10% after FMT. In contrast, Firmicutes increased in all AC infants. Previous work implied that Firmicutes decreased in patients with Cohn’s disease\(^{[23]}\), and the proportion of Firmicutes was negatively associated with gastrointestinal inflammation\(^{[24]}\).

After FMT, the relative abundances of Bacteroides and Lactobacillus increased. Prior reports showed that species in Bacteroides could secrete polysaccharide A, which promoted the number of T regulatory (Treg) cells\(^{[25,26]}\). Interleukin (IL)-10 produced by Treg cells also eliminated inflammatory reactions and protected against infectious pathogens\(^{[25,26]}\). Lactobacillus can secrete lactic acid, increase the proportion of Treg cells, and relieve symptoms of AC\(^{[8,27]}\). Generally, the relative abundance of opportunistic pathogens decreased, including Veillonella, Streptococcus, Clostridium, and Klebsiella. Prior reports suggested that the combination of Veillonella and Streptococcus had been found in various GM systems and can augment IL-8, IL-6, and tumor necrosis factor-α (TNF-α) responses, which were associated with inflammatory reactions\(^{[28]}\). Clostridium can cause diarrhea via enterotoxin secretion, and Klebsiella was positively associated with macrophage migration-inhibitory factor (MIF) and affected host immunity\(^{[29]}\). However, GM imbalance and post-FMT improvement need more analysis to understand the mechanisms underlying AC improvements.

This study pioneered the application of FMT in AC treatment and provided important reference to understand microbiota changes before and after FMT. Although the results favor the application of FMT for AC treatment, it is still important to clarify whether AC symptoms can be improved in our future studies with larger sample size. Also, we will explore the microbiota changes at the gene or functional level before and after FMT, to further the understanding of GM imbalance and re-configuration during FMT treatment of infantile AC.

Liu SX et al. FMT for infantile AC treatment


21 van den Bogert B, Meijerink M, Zoetendal EG, Wells JM, Klaerebezen M. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota.
Liu SX et al. FMT for infantile AC treatment


P- Reviewer: Daniel F, Iizuka M, Owczarek D S- Editor: Ma YJ
L- Editor: Wang TQ E- Editor: Ma YJ
